Longin A, Fontaniere B, Berger-Dutrieux N, Devonec M, Laurent J C
Centre Léon Berard, Lyon, France.
Cancer. 1990 Mar 15;65(6):1412-7. doi: 10.1002/1097-0142(19900315)65:6<1412::aid-cncr2820650628>3.0.co;2-a.
The monoclonal antibody (MoAb) BL2-10D1 directed against a tumor-associated antigen of human bladder cancer was used to identify tumor cells obtained by bladder washing or voided urine. The reactivity of BL2-10D1 MoAb was detected by an immunoperoxidase method and evaluated in ten healthy donors and in a series of 65 patients. The 65 patients studied were divided into three groups: ten with nontumor bladder disease (group A); 36 with bladder carcinoma (group B); and 19 with a history of bladder neoplasia but no visible tumor at the time of cytologic sampling (group C). The results were compared with the standard cytologic diagnosis on Papanicolaou-stained preparations. Conventional cytologic study showed a high false-negative rate in low-grade tumors (transitional cell carcinomas [TCC] Grades 1 and 2, 1/4 and 4/17, respectively). All urine from patients with a histologically proved TCC Grade 1 were stained with BL2-10D1 MoAb. Cytologic findings from patients with TCC Grade 2 (17 cases) contained positive cells in 14 cases and failed to react in three cases. Furthermore, whereas urine from patients with TCC Grade 2 or 3 was not always stained with BL2-10D1 MoAb, all patients with dysplastic lesions (three cases) or carcinoma in situ (5 cases) showed a positive reactivity. Such results suggest that BL2-10D1 MoAb may be considered as a valuable adjunct to the classical methods of early detection and follow-up of bladder cancer. However, a larger scale study is needed for MoAb BL2-10D1 to be proposed as an aid to improve the diagnostic sensitivity of urine cytologic investigation in the follow-up of patients treated for recurring bladder cancer, and for the screening of workers exposed to potent bladder carcinogens.
针对人膀胱癌肿瘤相关抗原的单克隆抗体（MoAb）BL2-10D1被用于识别通过膀胱冲洗或排尿获取的肿瘤细胞。采用免疫过氧化物酶法检测BL2-10D1单克隆抗体的反应性，并在10名健康供体和65例患者中进行评估。所研究的65例患者分为三组：10例患有非肿瘤性膀胱疾病（A组）；36例患有膀胱癌（B组）；19例有膀胱肿瘤病史但在细胞学采样时未发现可见肿瘤（C组）。将结果与巴氏染色涂片的标准细胞学诊断进行比较。传统细胞学研究显示低级别肿瘤（移行细胞癌[TCC]1级和2级，分别为1/4和4/17）的假阴性率较高。所有经组织学证实为TCC 1级患者的尿液均被BL2-10D1单克隆抗体染色。TCC 2级患者（17例）的细胞学检查结果显示，14例含有阳性细胞，3例无反应。此外，虽然TCC 2级或3级患者的尿液并非总是被BL2-10D1单克隆抗体染色，但所有发育异常病变患者（3例）或原位癌患者（5例）均显示阳性反应。这些结果表明，BL2-10D1单克隆抗体可被视为膀胱癌早期检测和随访经典方法的有价值辅助手段。然而，需要进行更大规模的研究，以便将BL2-10D1单克隆抗体作为一种辅助手段，用于提高复发性膀胱癌患者随访中尿液细胞学检查的诊断敏感性，以及用于筛查接触强效膀胱致癌物的工人。
